Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH
Recruiting now · Phase 2
Conditions studied: Langerhans Cell Histiocytosis
In brief
Treatment of Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis (LCH) Using a Low-Dose Cytarabine Combined with Thalidomide Regimen.
Key facts
- Study ID
- NCT07187193
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- People needed
- 50
- Starts
- 2025-04-12
- Expected to finish
- 2027-04-13
- Last updated by the study team
- 2025-09-22
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Clearly diagnose and treat adult patients with multisystem or single-system multifocal LCH;
- Aged between 18 and 70 years;
- Multisystem involvement or single-system multifocal disease;
- No prior systemic treatment (patients who have only received local radiotherapy or surgery may be enrolled);
- ECOG performance status score ≤ 2;
- Judged by clinicians as suitable for treatment with this protocol;
- Patients or their families able to understand the study protocol and willing to participate in the study, providing written informed consent.
You may not qualify if…
- Patients with LCH involving the central nervous system;
- Single-system single-lesion LCH;
- Subjects who have undergone major surgery within 4 weeks prior to the first dose in the study;
- Subjects who have received radiotherapy within 4 weeks prior to the first dose in the study; subjects with a history of myocardial infarction within the past year;
- Patients with New York Heart Association (NYHA) class 3 or 4 congestive heart failure, or a history of NYHA class 3 or 4 congestive heart failure;
- Pregnant or lactating women;
- Abnormal liver and kidney function: creatinine level ≥176.8μmol/l (2mg/dl), transaminase and bilirubin levels more than 2 times the upper limit of normal (for LCH patients with liver involvement, bilirubin levels more than 10 times the upper limit of normal);
- Abnormal blood counts: absolute neutrophil count less than 1×10\^9/L, platelet count less than 50×10\^9/L;
- Patients or their families unable to understand the conditions and objectives of this study;
- Any other circumstances in which the investigator deems the patient unsuitable to participate in this trial.
Where it is running
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.